EIKCS 2021: A Virtual Experience 23-24 APRIL 2021 - International Kidney Cancer Association ...
←
→
Page content transcription
If your browser does not render page correctly, please read the page content below
EIKCS 2021: A Virtual Experience 23-24 APRIL 2021 S Y M P O S I U M G U I D E
Table of Contents Welcome Letter........................................................................................................................2 About the Kidney Cancer Association...................................................................................3 2021 Kidney Cancer Association Board of Directors..........................................................5 2021 Kidney Cancer Association Medical Steering Committee and Clinical Advisory Board........................................................................................................................................ 6 Virtual Environment............................................................................................................... 8 Maximizing Your Symposium Experience............................................................................. 11 Continuing Medical Education Information....................................................................... 12 Agenda.................................................................................................................................... 17 Scientific Planning Committee............................................................................................ 19 Faculty....................................................................................................................................20 Sponsors................................................................................................................................. 24 Poster Listings ...................................................................................................................... 25 We encourage all attendees to share their EIKCS experience on social media. Make sure to add the hashtag #EIKCS2021 and tag @KidneyCancer in all your posts! EARN. ENGAGE. WIN. By participating in the EIKCS 2021, you are eligible to win fun prizes! Earn points throughout the virtual experi- ence by visiting exhibit booths, participating in poster presentations, attending sessions, and chatting with attend- ees. You can see how you are tracking against fellow attendees on the Leaderboard of the Virtual Experience. The attendees with the highest number of points by 14:05 GMT +1 on Saturday, 24 April 2021 will be entered to win complimentary registration to EIKCS 2022. 1
Welcome Letter KIDNEY CANCER ASSOCIATION
9450 SW Gemini Drive #38269
We are thrilled to welcome you to EIKCS 2021: A Virtual Beaverton, OR 97008-7105
Experience! The next two days promise an exciting program that P 847-332-1051
showcases the best in kidney cancer research and discovery. Toll Free: 800-850-9132
As a virtual experience, EIKCS 2021 is a fun and interactive office@kidneycancer.org
opportunity for participants from across the globe to join together
PRESIDENT AND CEO
and exchange ideas that will direct the future of kidney cancer re-
Gretchen E. Vaughan
search and treatment in the ultimate pursuit of a cure. Both our EU
and US attendees can earn CME credits for attendance. CHIEF ADVANCEMENT OFFICER
Kendall Monroe
This year, we are proud to feature David F. McDermott, MD, Chief,
Division of Medical Oncology at Beth Israel Deaconess Medical Cen- BOARD OF DIRECTORS
ter, who will give the EIKCS 2021 keynote address. Christopher G. Wood, MD, FACS,
Chairperson
Be sure to visit the exhibit hall, chat with fellow attendees in the Craig DePriester, Vice Chairperson
Networking Lounge, and participate in the not-to-be-missed Wood-
Noah Buntman, Treasurer
Fire session! As you share your thoughts and photos over social
Jamie Graves, Secretary
media, don’t forget to add the official hashtag: #EIKCS2021.
Lisa Alderson
We would like to express our gratitude to those who worked diligently Ronald M. Bukowski, MD
to make this virtual symposium a success including: Tessa Churchill, MD, MBA
• Our presenters and panelists for sharing their expertise and insights; Bradley Leibovich, MD, FACS
• Our sponsors, exhibitors, and attendees, whose support made Ryan Natzke
EIKCS 2021 possible; Eric Perakslis
• Our Scientific Program Planning Committee for their hours of David Perry, Esq.
hard work to craft a cutting-edge program – Frede Donskov, William J. Perry
MD, DMSc (Co-chair), Samra Turajlic, PhD, MRCP (Co-Chair),
Shelley Robson
Christian Beisland, MD, PhD, Guillermo de Velasco, MD, PhD,
Nicholas J. Vogelzang, MD
Lars Lund, MD, DMSci, Gabriel Malouf, MD, PhD, Thomas
Powles, MD, MBBS, MRCP, and Michael Staehler, MD, PhD. Laura Wood, RN, MSN, OCN
Ruben Ybarra
We are inspired by all you do in service of the kidney cancer community
and we couldn’t be prouder to support you and help lead the way to a MEDICAL STEERING COMMITTEE
future cure for kidney cancer. Have a wonderful symposium! Bradley C. Leibovich, MD, Chairperson
Jose Karam, MD, FACS
Sincerely, Laurence Albiges, MD, PhD
Axel Bex, MD, PhD
Gretchen E. Vaughan Ronald M. Bukowski, MD (Emeritus)
President and CEO Chung-Han (Joe) Lee, MD, PhD
Kidney Cancer Association
James Hsieh, MD, PhD
W. Kimryn Rathmell, MD, PhD
Christopher G. Wood, MD,
Chairman, Board of Directors Brian Rini, MD, FASCO, Vice-Chairperson
Kidney Cancer Association Walter M. Stadler, MD, FACP, (Emeritus)
Nizar M. Tannir, MD, FACP
Bradley C. Leibovich, MD, FACS Christopher G. Wood, MD, FACS
Chair, Medical Steering Committee
Kidney Cancer Association
22
About the Kidney Cancer Association
The Kidney Cancer Association was founded in 1990 by Eugene P. Schonfeld and a small group of patients and
doctors in Chicago, Illinois and has grown into an international non-profit organization. The KCA promotes scientific
advances through two annual research symposiums and a robust grant program, participates in legislative advocacy,
and seeks to be a source of education and resources for patients, caregivers, and anyone impacted by kidney cancer.
Our vision is to be the universal leader in finding the cure for kidney cancer.
Our mission is to be a global community dedicated to serving and empowering patients and caregivers, and leading
change through advocacy, research, and education.
One of the Association’s most important contributions is its
support of the physicians and nurses who care for kidney cancer
patients. Through our educational activities we help ensure that the
latest medical advances and best practices are shared. Our global
medical conferences bring together the world’s leading technology
and treatment options.
–Gretchen E. Vaughan, President and CEO, Kidney Cancer Association
MAIL DONATIONS TO:
Kidney Cancer Association
9450 SW Gemini Drive #38269
Beaverton, OR 97008-7105
Tel: 847-332-1051
office@kidneycancer.org
3
See You in Austin for IKCS 2021
KEYNOTE SPEAKER
Dr. James P. "Jim" Allison
2018 Nobel Prize in Physiology or Medicine
SAVE THE DATE
November 5–6, 2021
Austin, Texas, USA and online
Learn more at KCAMEETINGS.ORG
4
2021 Kidney Cancer Association Board of Directors
The Kidney Cancer Association would like to thank our 2021 Board Members!
BOARD OF DIRECTORS
Lisa Alderson David Perry, Esq.
Ronald M. Bukowski, MD William J. Perry
Noah Buntman Shelley Robson
Tessa Churchill, MD, MBA Gretchen E. Vaughan
Craig DePriester Nicholas J. Vogelzang, MD
Jamie Graves Christopher G. Wood, MD, FACS (Chair)
Bradley Leibovich, MD, FACS Laura Wood, RN, MSN, OCN
Ryan Natzke Ruben Ybarra
Eric Perakslis
Need more CME credits?
The Kidney Cancer Association is proud to offer free
CME sessions to healthcare professionals interested in
advancing their clinical knowledge in kidney cancer.
Learn more about our programs at KidneyCancer.org/cme-programming/
5
2021 Kidney Cancer Association
Medical Steering Committee and Clinical Advisory Board
MEDICAL STEERING COMMITTEE CLINICAL ADVISORY BOARD
Laurence Albiges, MD, PhD Nancy Ainslie, RN, BSN
Axel Bex, MD, PhD Julia Batten, APRN, MSN, MPH
Ronald M. Bukowski, MD (Emeritus) Nina Decker, MSW, LCSW
James Hsieh, MD, PhD Patricia Fisher, RN, MSN, ONC
Jose Karam, MD, FACS Jan Jackson, RN
Chung-Han (Joe) Lee, MD, PhD Kiran Kehoe, RN, BSN, CCRN
Bradley C. Leibovich, MD, FACS (Chair) Zita Lim, PA-C
W. Kimryn Rathmell, MD, PhD Nancy Moldawer, RN, MSN (Co-Chair)
Brian Rini, MD (Vice-Chairperson) Virginia J. Seery, MSN, RN, ANP-BC
Walter M. Stadler, MD, FACP (Emeritus) Meghara Walsh, RN, BSN
Nizar M. Tannir, MD, FACP Laura Wood, RN, MSN, OCN (Co-Chair)
Christopher G. Wood, MD, FACS
By putting lives
first, we’ve created
a legacy that lasts
Copyright © 2021 Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.
All rights reserved. HQ-NON-00309 02/20
6
INLYTA (axitinib) in combination
with pembrolizumab is indicated
for the first-line treatment of Learn more at
patients with advanced RCC INLYTAhcp.com
RCC=renal cell carcinoma.
Product Information is based on the US prescribing information.
IMPORTANT SAFETY INFORMATION
Hypertension including hypertensive crisis has been observed. Blood pressure should For patients with moderate hepatic impairment, the starting dose of INLYTA
be well controlled prior to initiating INLYTA. Monitor for hypertension and treat as should be decreased. INLYTA has not been studied in patients with severe hepatic
needed. For persistent hypertension despite use of antihypertensive medications, impairment.
reduce the dose. Discontinue INLYTA if hypertension is severe and persistent despite
use of antihypertensive therapy and dose reduction of INLYTA, and discontinuation INLYTA can cause fetal harm. Advise patients of the potential risk to the fetus
should be considered if there is evidence of hypertensive crisis. and to use effective contraception. When INLYTA is used in combination with
pembrolizumab, refer to the full Prescribing Information of pembrolizumab for
Arterial and venous thrombotic events have been observed and can be fatal. pregnancy and contraception information.
Use with caution in patients who are at increased risk for, or who have a history of,
these events. Avoid strong CYP3A4/5 inhibitors. If unavoidable, reduce the dose of INLYTA.
Grapefruit or grapefruit juice may also increase INLYTA plasma concentrations and
Hemorrhagic events, including fatal events, have been reported. INLYTA has not should be avoided.
been studied in patients with evidence of untreated brain metastasis or recent active
gastrointestinal bleeding and should not be used in those patients. If any bleeding Avoid strong CYP3A4/5 inducers and, if possible, avoid moderate CYP3A4/5 inducers.
requires medical intervention, temporarily interrupt the INLYTA dose.
Fatal adverse reactions (ARs) occurred in 3.3% of patients receiving INLYTA in
Cardiac failure has been observed and can be fatal. Monitor for signs or symptoms combination with pembrolizumab as first-line treatment for advanced RCC. These
of cardiac failure throughout treatment with INLYTA. Management of cardiac failure included 3 cases of cardiac arrest, 2 cases of pulmonary embolism, and 1 case each
may require permanent discontinuation of INLYTA. of cardiac failure, death due to unknown cause, myasthenia gravis, myocarditis,
Fournier’s gangrene, plasma cell myeloma, pleural effusion, pneumonitis, and
Gastrointestinal perforation and fistula, including death, have occurred. Use respiratory failure.
with caution in patients at risk for gastrointestinal perforation or fistula. Monitor
for symptoms of gastrointestinal perforation or fistula periodically throughout The most common (≥20%) ARs (all grades, vs sunitinib) occurring in patients receiving
treatment. INLYTA in combination with pembrolizumab as first-line treatment for advanced
RCC were diarrhea (56% vs 45%), fatigue/asthenia (52% vs 51%), hypertension (48%
Hypothyroidism requiring thyroid hormone replacement has been reported. Monitor vs 48%), hepatotoxicity (39% vs 25%), nausea (28% vs 32%), constipation (21% vs
thyroid function before initiation of, and periodically throughout, treatment. 15%), hypothyroidism (35% vs 32%), decreased appetite (30% vs 29%), palmar-
plantar erythrodysesthesia (28% vs 40%), stomatitis/mucosal inflammation (27% vs
INLYTA has the potential to adversely affect wound healing. Withhold INLYTA for at 41%), rash (25% vs 21%), dysphonia (25% vs 3.3%), and cough (21% vs 14%).
least 2 days prior to elective surgery. Do not administer INLYTA for at least 2 weeks
following major surgery and until adequate wound healing. The safety of resuming The most common (≥20%) Grade 3/4 ARs (vs sunitinib) occurring in patients
INLYTA after resolution of wound healing complications has not been established. receiving INLYTA in combination with pembrolizumab as first-line treatment for
advanced RCC were hypertension (24% vs 20%) and hepatotoxicity (20% vs 4.9%).
Reversible Posterior Leukoencephalopathy Syndrome (RPLS) has been observed. If
signs or symptoms occur, permanently discontinue treatment. The most common (≥20%) lab abnormalities (all grades, vs sunitinib) occurring
in patients receiving INLYTA in combination with pembrolizumab as first-line
Monitor for proteinuria before initiation of, and periodically throughout, treatment. treatment for advanced RCC included hyperglycemia (62% vs 54%), increased ALT
For moderate to severe proteinuria, reduce the dose or temporarily interrupt (60% vs 44%), increased AST (57% vs 56%), increased creatinine (43% vs 40%),
treatment with INLYTA. hyponatremia (35% vs 29%), hyperkalemia (34% vs 22%), hypoalbuminemia (32%
vs 34%), hypercalcemia (27% vs 15%), hypophosphatemia (26% vs 49%), increased
INLYTA in combination with pembrolizumab can cause hepatotoxicity with alkaline phosphatase (26% vs 30%), hypocalcemia (22% vs 29%), increased blood
higher than expected frequencies of Grades 3 and 4 alanine aminotransferase bilirubin (22% vs 21%), prolonged activated partial thromboplastin time (22% vs
(ALT) and aspartate aminotransferase (AST) elevation. Monitor ALT, AST, and 14%), lymphopenia (33% vs 46%), anemia (29% vs 65%), and thrombocytopenia
bilirubin before initiation of, and periodically throughout, treatment. Consider more (27% vs 78%).
frequent monitoring of liver enzymes as compared to when the drugs are used for
monotherapy. Consider withholding INLYTA and/or pembrolizumab, initiating Please see full Prescribing Information for INLYTA here or at INLYTAhcp.com
corticosteroid therapy, and/or permanently discontinuing the combination for severe
or life-threatening hepatotoxicity.
PP-INL-USA-0820 © 2021 Pfizer Inc. All rights reserved. March 2021
7
EIKCS 2021 Virtual Environment
VIRTUAL LOBBY
Click here for the Click here to chat
Click here to visit exhibitor
educational sessions. with attendees,
booths, chat with exhibitors,
Audience questions faculty, KOLs,
and learn about their newest
can be submitted while exhibitors, and
products and services.
watching the sessions. sponsors.
Click here to
Click here submit your
for the virtual feedback on
posters, to watch EIKCS!
oral abstract
presentations, and
ask questions of
Click here
the presenters.
to view the
Symposium
Guide, Agenda,
Instructions for
Navigating the
Virtual
Experience, or
to get Technical
Support.
COMMITTED TO A
GREATER
UNDERSTANDING
Together, Merck KGaA, Darmstadt, Germany
and Pfizer are dedicated to exploring
innovative approaches to help improve
treatment options for patients with cancer.
Copyright © 2021 Merck KGaA
Darmstadt, Germany
Merck KGaA, Darmstadt, Germany
All rights reserved. April 2021 GL-AVEKI-00030
8
EIKCS 2021 Virtual Environment Networking Lounge Auditorium Poster Hall Exhibit Hall Help Desk 9
2021 KCA Grants
Young Investigator Award (YIA)
Advanced Discovery Award (ADA)
Psychosocial Focus Award (PFA)
APR 29, 2021 Final day to submit LOI JUL 15, 2021 Final day to submit full
proposals for academic review
MAY 27, 2021 Final day that meritorious LOI
proposals notified to proceed SEP 21, 2021 Winning research teams
with full proposal notified
Learn more at KIDNEYCANCER.ORG
10Maximizing Your Symposium Experience
Here are some tips to make EIKCS 2021 an enjoyable and educational experience. Registration is required to access
presentations, sessions and ask questions of faculty.
GETTING THE MOST OUT OF THE SYMPOSIUM
1. Find a comfortable and quiet space to focus.
2. Plan to enter the conference 15 minutes before the first session to get familiar with navigating the
virtual platform.
3. Plan ahead and choose the sessions you want to join in advance.
4. Have a notebook and pen handy to capture notes from each session. You can also take notes directly on each
PowerPoint slide as it is presented. Notes and copies of the slide will be emailed directly to you a few days
following the conference.
5. You will join the conference using the link information provided to you via email a few days before the
conference.
6. All presentations will take place in the British Summer Time (BST) or Greenwich Mean Time (GMT+1).
7. Visit the help desk if you need technical support.
8. Visit the networking lounge to chat with faculty, exhibitors, and fellow presenters.
ENSURE A SMOOTH CONNECTION TO THE SYMPOSIUM
If using a desktop or laptop computer, connect your device to a hard-wired internet connection (not Wi-Fi) and
running at high-speed. Ensure all applications or any programs with notifications, pop-ups or reminders are closed
(e.g., Outlook, chat, calendar applications). Google Chrome and Mozilla Firefox are the preferred internet browsers.
ACCESS TO PRESENTATIONS AND VIDEOS
All presentations will be available to view on the virtual platform until 31 May 2021 for registered attendees. Then
they will be available on the KCAmeetings.org website.
EXHIBIT HALL HOURS
The exhibit hall is accessible at any time during the symposium. Visit the exhibit hall during scheduled break times
or at your leisure to learn more about the latest and greatest products and services, while networking with industry
leaders.
Exhibitors are available to chat with you to answer any questions you may have about their products and services.
Many booths have downloadable resources and videos demonstrating their product lines.
Check out the EIKCS 2021 exhibitors during the following break times:
Friday, 23 April Saturday, 24 April
11:35 - 12:00 GMT +1 11:05 - 11:30 GMT +1
13:30 - 13:40 GMT +1
POSTER HALL
The poster hall is accessible at any time during EIKCS 2021 and includes PDFs of the posters and video presentations
by each poster presenter. Stop by Friday from 15:00 to 15:30 for the Poster Walk where you can chat with poster
presenters within the platform, and join Gabriel Malouf, MD, PhD and Guillermo de Velasco, MD, PhD for a
discussion around the poster abstracts. The poster discussion will take place via the Zoom link found in the Poster Hall.
11Continuing Medical Education Information
Jointly provided by The France Foundation and The Kidney Cancer Association
TARGET AUDIENCE
This educational activity is intended for medical oncologists and urologists who treat patients with kidney cancer.
Fellows, trainees, nurses, nurse practitioners, physician assistants, and other healthcare professionals involved in the
management of kidney cancer are invited to participate.
STATEMENT OF NEED
Education and interaction surrounding the space of renal cell carcinoma are paramount to improving patient care.
This program is targeted to physicians, advocates and researchers to help promote learning and collaboration for
advancement in the renal cancer space.
EDUCATIONAL ACTIVITY LEARNING OBJECTIVES
Upon completion of this course, the participants should be able to:
• Characterize the various therapies currently available for locally advanced and metastatic renal cell carcinoma
• Identify the novel approaches to non-clear RCC patient management
• Understand the role of the tumor microenvironment in kidney cancer
• Discuss how to design biomarker driven clinical trials in kidney cancer
EACCME CREDITS (ECMEC®s)
The EIKCS 2021: A Virtual Experience, Old Lyme, United States, 23/04/2021-24/04/2021
has been accredited by the European Accreditation Council for Continuing Medical Education
(EACCME®) with 6 European CME credits (ECMEC®s). Each medical specialist should claim
only those hours of credit that he/she actually spent in the educational activity.
Through an agreement between the Union Européenne des Médecins Spécialistes and the American Medical
Association, physicians may convert EACCME® credits to an equivalent number of AMA PRA Category
1 Credits™. Information on the process to convert EACCME® credit to AMA credit can be found at
www.ama-assn.org/education/earn-credit-participation-international-activities.
Live educational activities, occurring outside of Canada, recognised by the UEMS-EACCME® for ECMEC®s are
deemed to be Accredited Group Learning Activities (Section 1) as defined by the Maintenance of Certification
Program of the Royal College of Physicians and Surgeons of Canada.
12Continuing Medical Education Information ACCREDITATION STATEMENT This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of The France Foundation and The Kidney Cancer Association. The France Foundation is accredited by the ACCME to provide continuing medical education for physicians. ACCME CREDIT DESIGNATION Physicians: The France Foundation designates this live activity for a maximum of 8.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. METHOD OF PARTICIPATION/HOW TO RECEIVE CREDIT 1. Review the activity objectives and CME/CE information. 2. Participate in the CME/CE activity. 3. Complete the CME/CE evaluation form, which provides each participant with the opportunity to comment on how participating in the activity will affect their professional practice; the quality of the instructional process; the perception of enhanced professional effectiveness; the perception of commercial bias; and his/her views on future educational needs. 4. If you are requesting educational credits or a certificate of participation, your certificate will be available for download. DISCLOSURE POLICY In accordance with the ACCME Standards for Commercial Support, The France Foundation (TFF) and The Kidney Cancer Association (KCA) require that individuals in a position to control the content of an educational activity disclose all relevant financial relationships with any commercial interest. TFF and KCA resolve all conflicts of interest to ensure independence, objectivity, balance, and scientific rigor in all their educational programs. Furthermore, TFF and KCA seek to verify that all scientific research referred to, reported, or used in a CME/CE activity conforms to the generally accepted standards of experimental design, data collection, and analysis. TFF and KCA are committed to providing learners with high-quality CME/CE activities that promote improvements in health care and not those of a commercial interest. ACTIVITY STAFF DISCLOSURES The planners, reviewers, editors, staff, CME committee, or other members at The France Foundation who control content have no relevant financial relationships to disclose. The planners, reviewers, editors, staff, CME committee, or other members at The Kidney Cancer Association who control content have no relevant financial relationships to disclose. 13
Continuing Medical Education Information
FACULTY DISCLOSURES
The following faculty report that they have relevant financial relationships to disclose:
• Laurence Albiges has received grants/research support from Bristol-Myers Squibb and honoraria or consultation
fees from Bristol-Myers Squibb, MSD, Pfizer, and Novartis.
• Christian Beisland has received honoraria or consultation fees from Pfizer.
• Karim Bensalah has received grants/research support from Pfizer and has received honoraria or consultation fees
from Ipsen, Bristol-Myers Squibb, MSD, and Intuitive.
• Alex Bex has received grants/research support from Pfizer and Bristol-Myers Squibb.
• Toni K. Choueiri has received grants/research support from Exelixis and GSK. He has received honoraria or
consulting fees from AstraZeneca, Bristol Myers-Squibb, Eisai, Eli Lilly, EMD Serono, Exelixis, Merck, Novartis,
and Pfizer.
• Saeed Dabestani has received honoraria from Pfizer and served as a medical advisor for Elypta AB.
• Guillermo de Velasco has received grants/research support from Ipsen, Pfizer, and Roche. He has received
honoraria or consultation fees from Pfizer, Roche, MSD, Astellas, Bayer, Ipsen, Merck, EUSA Pharma, and
Bristol-Myers Squibb.
• Frede Donskov has received grants/research support from Pfizer, Ipsen, and MSD.
• John B. A. G. Haanen has received grants/research support from Amgen, Bristol-Myers Squibb, BioNTech, and
Neogene Therapeutics. He has received honoraria or consultation fees from Achilles Therapeutics, Bristol-Myers
Squibb, and BioNTech. He is a stock shareholder of Neogene Therapeutics.
• Hans Hammers has received honoraria from Bristol-Myers Squibb. He has served as a consultant for ARMO
BioSciences, Bayer, Corvus Pharmaceuticals, Exelixis, Lilly, Merck, Novartis, Pfizer, and Surface Oncology. He
has received research funding from Bristol-Myers Squibb and Merck.
• Gabriel Malouf has received honoraria or consultation fees from Ipsen and Bristol-Myers Squibb.
• David F. McDermott has received research support from Bristol-Myers Squibb, Merck, Genentech, Pfizer,
Exelixis, X4 Pharma, Alkermes, Inc., and Checkmate Pharmaceuticals. He has received honoraria and
consultation fees from Bristol-Myers Squibb, Pfizer, Merck, Alkermes, Inc., EMD Serono, Eli Lilly and
Company, Iovance, Eisai Inc., Werewolf Therapeutics, and Calithera Biosciences.
• Arnaud Mejean has received honoraria or consultation fees from Pfizer, Novartis, GSK, and Bristol-Myers
Squibb.
• Sylvie Négrier has received grants/research support from Pfizer and Ipsen, and received honoraria or
consultation fees from Pfizer, Bristol-Myers Squibb, Ipsen, Novartis, and MSD.
• Lisa Pickering has received grants/research support from NIHR and Rosetrees Trust, and has received honoraria
or consultation fees from Bristol-Myers Squibb, Eisai, MSD, Novartis, and Pfizer.
• Camillo Porta has received honoraria or consultation fees from MSD, Bristol-Myers Squibb, AstraZeneca,
Merck, EUSA, Eisai, Ipsen, and Angelini. He has participated in company sponsored speaker bureaus for MSD,
Bristol-Myers Squibb, AstraZeneca, EUSA, Ipsen, and General Electric.
• Thomas Powles has received grants/research support from AstraZeneca, Roche, and Bristol-Myers Squibb. He
has received honoraria or consultation fees from AstraZeneca, Roche, and Incyte.
14Continuing Medical Education Information
FACULTY DISCLOSURES
• Brian I. Rini is employed by an institution that has received grants/research support from Pfizer, Hoffman-
LaRoche, Incyte, AstraZeneca, Taris, Seattle Genetics, Arrowhead Pharmaceuticals, Immunomedics, Bristol-
Myers Squibb, Mirati Therapeutics, Merck, Surface Oncology, Dragonfly Therapeutics, Aravive, and Exelixis.
He has received consulting fees from Bristol-Myers Squibb, Pfizer, Genentech/Roche, Aveo, Synthorx,
Compugen, Merck, Corvus, Surface Oncology, 3DMedicines, Aravive, Alkermes, Arrowhead, GSK, Shionogi,
and Eisai. He owns stock in PTC Therapeutics.
• Manuela Schmidinger has received honoraria or consultation fees from Pfizer, Roche, Ipsen, Exelixis, Bristol-
Myers Squibb, MSD, Merck, EUSA, Eisai and Alkermes.
• Barbara Seliger has received grants/research support from Bristol-Myers Squibb, and has received honoraria or
consultation fees from Pfizer and Merck.
• Michael Staehler has received grants/research support from Pfizer, GlaxoSmithKline, AVEO, Bristol-Myers
Squibb, Novartis, Bayer, Roche/Genentech, Immatics, Wilex, Ipsen, Exelixis, and Eisai. He has received
honoraria or consultation fees from Pfizer, GlaxoSmithKline, AVEO, Novartis, Bayer, EUSA Pharmaceuticals,
Astellas, Ipsen, Exelixis, Pelloton, Eisai, Bristol-Myers Squibb, MSD, and Apogepha. He has participated in
company sponsored speaker bureaus for Pfizer, GlaxoSmithKline, Novartis, Bayer, EUSA Pharmaceuticals,
Ipsen, Exelixis, Pelloton, Eisai, Bristol-Myers Squibb, MSD, and Apogepha.
• Nizar Tannir has received grants/research support and honoraria or consultation fees from Bristol-Myers-Squibb
and Pfizer.
• Samra Turajlic has received grants/research support from CRUK, NIHR, Royal Marsden, and has received
honoraria or consultation fees from AstraZeneca, Novartis, and Roche.
• Yann-Alexandre Vano has received honoraria or consultation fees from Bristol-Myers Squibb, Ipsen, MSD, and
Novartis.
• Tom Waddell has received grants/research support from Bristol-Myers Squibb, Eisai, Ipsen, MSD, Novartis,
Pfizer and Roche. He has received honoraria or consultation fees from Bristol-Myers Squibb, Eisai, EUSA
Pharmaceuticals, Ipsen, MSD, Pfizer and Roche.
• Christopher G. Wood has received grants/research support from Mirait and Colmmune. He has received
honoraria or consultation fees from Merck and Pfizer, and has participated in a company sponsored speakers
bureau with Merck and Pfizer.
The faculty listed below report that they have no relevant financial relationships to disclose:
• Mark W. Ball
• Bernard Escudier
• Catherine Sautès-Fridman
• Lars Lund
• Holger Moch
• Tim O’Brien
• Maxine Tran
• Alessandro Volpe
15Continuing Medical Education Information DISCLOSURE OF UNLABELED USE TFF and KCA require CME faculty (speakers) to disclose when products or procedures being discussed are off label, unlabeled, experimental, and/or investigational, and any limitations on the information that is presented, such as data that are preliminary, or that represent ongoing research, interim analyses, and/or unsupported opinion. Faculty in this activity may discuss information about pharmaceutical agents that is outside of US Food and Drug Administration approved labeling. This information is intended solely for continuing medical education and is not intended to promote off-label use of these medications. TFF and KCA do not recommend the use of any agent outside of the labeled indications. If you have questions, contact the Medical Affairs Department of the manufacturer for the most recent prescribing information. DISCLAIMER The France Foundation and The Kidney Cancer Association present this information for educational purposes only. The content is provided solely by faculty who have been selected because of recognized expertise in their field. Participants have the professional responsibility to ensure that products are prescribed and used appropriately on the basis of their own clinical judgment and accepted standards of care. The France Foundation and The Kidney Cancer Association assume no liability for the information herein. 16
EIKCS 2021 23–24 APRIL 2021
Agenda
Day 1 — 23 April 2021
TIME (GMT +1) SESSION TITLE FACULTY NAME
10:00 - 10:05 Welcome and Demographic Questions Samra Turajlic, MD, PhD, MRCP
Chairs:
Lars Lund, MD, DMSci; and Michael Staehler, MD, PhD
Panelists:
10:05 - 11:35 Surgical Session Panel Discussion Karim Bensalah, MD, PhD; Tim O’Brien, DM, MA,
FRCS (Urology); Saeed Dabestani, MD, PhD;
Arnaud MeJean, MD, PhD; Maxine Tran, MD, PhD,
FRCS (UROL); and Alessandro Volpe, MD
11:35 - 12:00 Break
Chairs: Thomas Powles, MD, MBBS, MRCP; and
12:00 - 13:00 Systemic Therapy Session
Manuela Schmidinger, MD
Treating with VEGF + IO or Ipi/Nivo: Which
12:00 - 12:10 Brian I. Rini, MD, FASCO
Approach?
Modern Therapeutic Approaches in Second-Line and
12:10 - 12:20 Camillo Porta, MD
Later Therapies
12:20 - 12:30 Discussion and Q&A
Tissue-Based Biomarkers for Potential Clinical Adoption
12:30 - 12:40 Thomas Powles, MD, MBBS, MRCP
in Renal Cancer
Circulating Biomarkers for Potential Clinical Adoption
12:40 - 12:50 Toni K. Choueiri, MD
in Renal Cancer
12:50 - 13:00 Discussion and Q&A
Chairs:
Lars Lund, MD, DMSci; and Gabriel Malouf, MD, PhD
Panelists:
13:00 - 13:30 Non–Clear Cell Panel Discussion
Laurence Albiges, MD, PhD; Mark Ball, MD; Axel Bex,
MD, PhD; Holger Moch, MD; Manuela Schmidinger, MD;
and Nizar M. Tannir, MD, FACP
13:30 - 14:15 Break
Keynote Lecture: Kidney Cancer as a Model for a
14:15 - 15:00 David F. McDermott, MD
Curable Neoplasm
15:00 Closing Remarks and Adjournment Frede Donskov, MD, DMSc
15:00 - 15:30 Poster Walk in the Poster Hall
15:30 - 16:00 Networking Discussion in the Networking Lounge
17EIKCS 2021 23–24 APRIL 2021
Agenda
Day 2 — 24 April 2021
TIME (GMT +1) SESSION TITLE FACULTY NAME
10:00 - 10:05 Welcome Samra Turajlic, MD, PhD, MRCP
Chairs: Lars Lund, MD, DMSci; and Samra Turajlic,
10:05 - 11:05 New Directions/Management of Systemic Therapies
MD, PhD, MRCP
10:05 - 10:20 Future Therapeutic Approaches in RCC Hans Hammers, MD, PhD
Designing Biomarker-Driven Trials: Opportunities
10:20 - 10:35 Yann-Alexandre Vano, MD, PhD
and Challenges
10:35 - 10:50 Impact and Manipulation of Microbiomes Lisa Derosa, MD, PhD
10:50 - 11:05 Discussion and Q&A
11:05 - 11:30 Break
Chairs: Bernard J. Escudier, MD; and John B. Haanen,
11:30 - 12:30 Basic Science Session
MD, PhD
11:30 - 11:45 Role of the Tumor Microenvironment in Renal Cancer Barbara Seliger, PhD
Targeting the Tumor Microenvironment in Renal Can-
11:45 - 12:00 Catherine Sautès-Fridman, MD
cer: The Role of T and B Cells
12:00 - 12:15 What Is the Source of Immune Infiltration in RCC? Samra Turajlic, MD, PhD, MRCP
12:15 - 12:30 Discussion and Q&A
Moderator:
Christopher G. Wood, MD, FACS
Panelists:
12:30 - 14:00 WoodFire Session Laurence Albiges, MD, PhD; Christian Beisland, MD,
PhD; Hans Hammers, MD, PhD; Lars Lund, MD,
DMSci; Sylvie Negrier, MD, PhD; Lisa Pickering, PhD,
FRCP; and Tom Waddell, MBChB, MRCP, MD (Res)
14:00 - 14:05 Closing Remarks and Adjournment Frede Donskov, MD, DMSc
18Scientific Planning Committee
Christian Beisland, MD, PhD Guillermo de Velasco, MD, PhD Frede Donskov, MD, DMSc
Professor and Chair, Medical Oncologist Clinical Professor,
Department of Urology Hospital 12 de Octubre Department of Oncology
Haukeland University Hospital Madrid, Spain Aarhus University Hospital
Bergen, Norway Aarhus, Denmark
Lars Lund, MD, DMSci Gabriel Malouf, MD, PhD Thomas Powles, MD, MBBS,
Consultant and Professor, Professor of Medical Oncology MRCP
Department of Urology Strasbourg Europe Cancer Institute Professor of Genitourinary
Odense University Hospital Strasbourg, France Oncology
University of Southern Denmark Barts Cancer Institute
Odense, Denmark London, United Kingdom
Michael Staehler, MD, PhD Samra Turajlic, MD, PhD, MRCP
Professor of Urology Consultant Medical Oncologist
Ludwig-Maximilian University The Royal Marsden Hospital
Munich, Germany London, United Kingdom
19Faculty
Laurence Albiges, MD, PhD Mark W. Ball, MD Christian Beisland, MD, PhD
Medical Oncologist Associate Director, Urologic Professor and Chair,
Gustave Roussy Institute Oncology Fellowship Department of Urology
Villejuif, France National Cancer Institute Haukeland University Hospital
Bethesda, Maryland, USA Bergen, Norway
Karim Bensalah, MD, PhD Axel Bex, MD, PhD Toni K. Choueiri, MD
Professor of Urology Professor of Urology Chief Director, Lank Center
University of Rennes The Netherlands Cancer Institute for Genitourinary Oncology
Rennes, France Amsterdam, Netherlands Dana-Farber Cancer Institute
Boston, Massachusetts, USA
Saeed Dabestani, MD, PhD Guillermo de Velasco, MD, PhD Lisa Derosa, MD, PhD
Consultant Urologist Medical Oncologist Medical Oncology
Deptartment of Translational Hospital 12 de Octubre Gustave Roussy Institute
Medicine Madrid, Spain Villejuif, France
Division of Urological Cancers
Lund University
Kristianstad Central Hospital
Malmo, Sweden
20Faculty
Frede Donskov, MD, DMSc Bernard Escudier, MD Catherine Sautès-Fridman, MD
Clinical Professor, Chair, Genitourinary Professor Emeritus
Department of Oncology Oncology Committee Paris Descartes University
Aarhus University Hospital Gustave Roussy Institute Paris, France
Aarhus, Denmark Villejuif, France
John B. A. G. Haanen, MD, PhD Hans Hammers, MD, PhD Lars Lund, MD, DMSci
Professor of Translational Eugene P. Frenkel, MD, Consultant and Professor,
Immunotherapy of Cancer Scholar in Clinical Medicine Department of Urology
Leiden University Medical Center Associate Professor of Internal Medicine Odense University Hospital
Head, Division of Medical Oncology Division of Hematology-Oncology University of Southern Denmark
The Netherlands Cancer Institute UT Southwestern Medical Center Odense, Denmark
Amsterdam, Netherlands Dallas, Texas, USA
Gabriel Malouf, MD, PhD David F. McDermott, MD Arnaud MeJean, MD, PhD
Professor of Medical Oncology Chief, Division of Medical Oncology Professor
Strasbourg Europe Cancer Beth Israel Deaconess Medical Center University of Paris
Institute Leader, Kidney Cancer Program Paris, France
Strasbourg, France Dana-Farber/Harvard Cancer Center
Professor of Medicine
Harvard Medical School
Boston, Massachusetts, USA
21Faculty
Holger Moch, MD Sylvie Négrier, MD, PhD Tim O’Brien, DM, MA, FRCS
Professor of Pathology Professor (Urology)
University Hospital Zurich Centre Léon Bérard Consultant Urological Surgeon
Zurich, Switzerland Lyon, France Urology Center Guy’s Hospital
Chairman, Section of Oncology
British Association of Urological
Surgeons
London, United Kingdom
Lisa Pickering, PhD, FRCP Camillo Porta, MD Thomas Powles, MD, MBBS,
Consultant Medical Oncologist Chair, Oncology MRCP
The Royal Marsden Hospital Department of Biomedical Sciences Professor of Genitourinary
London, United Kingdom and Human Oncology Oncology
University of Bari “A. Moro” Barts Cancer Institute
Chief, Division of Medical Oncology London, United Kingdom
Bari Consortia Polyclinic
Bari, Italy
Brian I. Rini, MD Manuela Schmidinger, MD Barbara Seliger, PhD
Professor of Medicine Professor of Medicine Director of the Institute
Chief, Clinical Trials Department of Urology MLU Halle-Wittenberg, Institute
Vanderbilt-Ingram Cancer Center Medical University of Vienna of Medical Immunology
Nashville, Tennessee, USA Vienna, Austria Halle (Saale), Germany
22Faculty
Michael Staehler, MD, PhD Nizar M. Tannir, MD, FACP Maxine Tran, MD, PhD,
Professor of Urology Professor, Department of FRCS (Urol)
Ludwig-Maximilian University Genitourinary Medical Oncology Associate Professor of Renal
Munich, Germany University of Texas MD Anderson Cancer
Cancer Center University College London
Houston, Texas, USA London, United Kingdom
Samra Turajlic, MD, PhD, MRCP Yann-Alexandre Vano, MD, PhD Alessandro Volpe, MD
Consultant Medical Oncologist Medical Oncologist Associate Professor of Urology
The Royal Marsden Hospital Department of Medical Oncology University of Eastern Piedmont
London, United Kingdom Georges-Pompidou European Hospital Hospital
Paris Public Hospital Assistance, Chairman, Division of Urology
Paris-Centre Maggiore Della Carità Hospital
Cordeliers Research Center,
Novara, Italy
Sorbonne University,
University of Paris
Paris, France
Tom Waddell, MBChB, MRCP, Christopher G. Wood, MD, FACS
MD (Res) Professor and Deputy Chairman,
Consultant Medical Oncologist Department of Urology
The Christie NHS Foundation Trust Division of Surgery
Manchester, United Kingdom The University of Texas
MD Anderson Cancer Center
Houston, Texas, USA
23EIKCS 2021 is Made Possible with the Generous Support of: 24
Poster Listings
TO VIEW POSTER PRESENTATIONS DURING EIKCS 2021, PLEASE VISIT THE VIRTUAL POSTER HALL.
Poster
Title Lead Author Name
Number
Clinicopathological criteria of renal cell carcinoma in the past 6 years: a
1 Mohamed Ashour Abouagour
single-center experience
2 Soluble PD-L1 and CD163 have prognostic value in renal cell carcinoma Sabina Davidsson
Assessment of angiogenesis by Dynamic Contrast-Enhanced Computed
Tomography Parameters Blood Volume and Blood Flow compared with Core
3 Aska Drljevic-Nielsen
Biopsy Identified Microvessel Density in Patients with Metastatic Renal Cell
Carcinoma
Feasibility of cell-free circulating tumor DNA (ctDNA) in metastatic renal cell
4 carcinoma (mRCC) and impact of temporal heterogeneity on agreement with Jasnoor Malhotra
tissue-based molecular testing using a multi-institutional cohort
A comparison of whole exome sequencing and targeted sequencing platforms
5 Ameish Govindarajan
in patients with metastatic renal cell carcinoma (mRCC)
The modified Glasgow Prognostic Score predicts survival in metastatic renal
6 Qiu Ginj Kong
cell carcinoma
Axitinib and Avelumab (AA) for metastatic renal cell carcinoma (mRCC) – A
7 Jennifer Allison
real-world UK review
Biomarkers of systemic inflammation in patients on active surveillance for
8 Vishwani Chauhan
metastatic renal cell carcinoma
Ipilimumab and Nivolumab (I+N) for metastatic renal cell carcinoma (mRCC)
9 Jennifer Allison
– A real-world UK review
TIVO-3: Tivozanib Benefits Multiple Subgroups for Progression-Free
10 Survival Compared to Sorafenib in Subjects with Refractory Advanced Renal Camillo Porta
Cell Carcinoma (RCC).
Plasma cytokine concentrations are associated with gut microbial composition
11 Sabrina Salgia
in metastatic renal cell carcinoma (mRCC)
Stereotactic Body Radiation Therapy (SBRT) For Prolongation of Systemic
12 Nicholas Salgia
Therapy in Oligoprogressive Metastatic Renal Cell Carcinoma (mRCC)
THINK TKI, THINK CABOMETYX®
CABOMETYX® (cabozantinib) is indicated for the treatment of advanced renal cell carcinoma (RCC):1
• in treatment-naïve adults with intermediate or poor risk per IMDC criteria
• in adults following prior vascular endothelial growth factor (VEGF)-targeted therapy.
This material is intended solely for healthcare professionals, with the exception of US and Japan healthcare
professionals. You are viewing the digital program of an International Virtual Congress run by the Kidney
Cancer Association and provided to HCPs from around the world. For purposes of EIKCS 2021, best efforts were
undertaken by the Kidney Cancer Association and Ipsen to ensure compliance with the EFPIA and UK Codes
of Practice, however, you should review your local prescribing information and consult directly the local affiliate
of Ipsen to address any questions. Prescribing information may vary depending on local approval in each country.
Prescribing information, adverse Therefore, before prescribing any product, always refer to local materials such as the prescribing information
event reporting and list of countries and/or the Summary of Product Characteristics (SPC).
where CABOMETYX® is licensed
1. CABOMETYX Summary of Product Characteristics. CBZ-ALL-002605 CMX-GB-000864 April 2021
25See You in Antwerp
for EIKCS 2022
SAVE THE DATE
22–23 April 2022
Antwerp, Belgium
Learn more at KCAMEETINGS.ORG
26The Kidney Cancer Association is a global community dedicated to serving and empowering patients and caregivers, and leading change through advocacy, research, and education in order to be the universal leader in finding a cure for kidney cancer. KIDNEYCANCER.ORG office@kidneycancer.org 800-850-9132 MAILING ADDRESS Kidney Cancer Association 9450 SW Gemini Drive #38269 Beaverton, OR 97008-7105 HEADQUARTERS Houston, Texas, USA @KidneyCancer | #UnstoppableTogether
You can also read
